MIRM News and Press, Mirum Pharmaceuticals Inc. From 11/03/23

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to participate in a fireside chat at the 2023 UB...

2023-11-02 16:51:04 ET Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q3 GAAP EPS of -$0.57. Revenue of $47.7M (+153.7% Y/Y). For further details see: Mirum Pharmaceuticals GAAP EPS of -$0.57, revenue of $47.7M

- Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in H1 2024 - Conference call to provide business updat...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Mirum Pharmaceuticals Inc. (MIRM) is expected to report $-0.64 for Q3 2023

- Late-breaker poster presentation accepted featuring LIVMARLI ® data showing long-term maintenance of response in patients with PFIC - Four poster presentations will highlight LIVMARLI PFIC data and volixibat proof-of-concept trial data in intrahepatic cholestasis of pregnancy ...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2 nd , 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress. Conference call ...

2023-10-17 17:25:51 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript Mirum Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call ...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive...

2023-10-13 17:12:53 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals For further details see: Mirum Pharmaceuticals to sell 7.94M shar...